表达萤火虫荧光素酶的呼吸道合胞病毒(RSV)在活体小鼠中的生物发光成像及其用于治疗药物和疫苗评价
研究开发了表达萤火虫荧光素酶的RSV A2株(RSVA2-line19-FFL)活体小鼠全身生物发光成像模型,鼻内感染后可在鼻腔和肺部检测到强生物发光信号,其动力学与病毒滴度及病毒RNA高度相关;pre-fusion F蛋白疫苗接种诱导高滴度中和抗体并强效抑制鼻腔和肺部病毒复制,而帕利珠单抗感染后2天治疗仅在第4天减少鼻腔病毒复制、第5天对肺部病毒载量仅有 modest 降低,且斑块试验第5天未检出肺部病毒滴度,差异源于帕利珠单抗包被病毒颗粒阻断体外靶细胞感染,凸显活体成像在RSV治疗评价中的价值。
要点
- RSVA2-line19-FFL鼻内感染BALB/c小鼠后鼻腔和肺部可检测到强生物发光信号。
- 活体成像定量的肺部病毒复制动力学与斑块试验病毒滴度及qRT-PCR病毒RNA高度相关。
- pre-fusion F蛋白疫苗诱导高滴度中和抗体,强效保护鼻腔和肺部免受病毒复制。
核心结论
- 该重组RSV活体成像动物模型便捷且有价值,可用于研究RSV宿主播散及评价抗病毒化合物和疫苗。
研究设计与样本
- 研究开发了表达萤火虫荧光素酶的RSV A2株(RSVA2-line19-FFL)活体BALB/c小鼠全身生物发光成像模型,用于活体小鼠中抗病毒药物和疫苗效果评价。
主要发现
- 鼻内感染RSVA2-line19-FFL后,小鼠鼻腔和肺部检测到强生物发光信号。
- 每日活体成像定量的肺部病毒复制动力学与离体斑块试验测定的病毒滴度及qRT-PCR测定的病毒RNA高度相关。
- pre-fusion F蛋白疫苗接种小鼠诱导高滴度中和抗体,对鼻腔和肺部病毒复制产生强保护免疫。
- 感染后2天帕利珠单抗治疗小鼠第4天鼻腔病毒复制减少,第5天肺部病毒载量仅 modest 降低。
- 帕利珠单抗治疗动物第5天斑块试验未检出肺部病毒滴度,差异源于帕利珠单抗包被病毒颗粒阻断体外靶细胞感染。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Respiratory Syncytial virus (RSV) is one of the leading causes of pneumonia among infants with no human vaccine or efficient curative treatments. Efforts are underway to develop new RSV vaccines and therapeutics. There is a dire need for animal models for preclinical evaluation and selection of products against RSV. Herein, we developed a whole body bioluminescence imaging to follow replication of RSV A2 virus strain expressing firefly luciferase (RSVA2-line19-FFL) in live BALB/c mice that can be used as an extremely sensitive readout for studying effects of antiviral and vaccines in living mice. Strong bioluminescence signal was detected in the nasal cavity and in the lungs following intranasal infection of mice with RSVA2-line19-FFL. The kinetics of viral replication in lungs quantified by daily live imaging strongly correlated with viral titers measured by ex-vivo plaque assay and by assessing viral RNA by qRT-PCR. Vaccination of mice with a pre-fusion F protein elicited high neutralizing antibody titers conferring strong protective immunity against virus replication in the nasal cavity and lungs. In contrast, post-challenge treatment of mice with the monoclonal antibody Palivizumab two days after infection reduced viral replication in the nasal cavity at day 4, but only modestly reduced virus loads in the lungs by day 5. In contrast to RSV bioluminescence, plaque assay did not detect viral titers in lungs on day 5 in Palivizumab-treated animals. This difference between viral loads measured by the two assays was found to be due to coating of virions with the Palivizumab that blocked infection of target cells in vitro and shows importance of live imaging in evaluation of RSV therapeutics. This recombinant RSV based live imaging animal model is convenient and valuable tool that can be used to study host dissemination of RSV and evaluation of antiviral compounds and vaccines against RSV.
引用
- Fuentes S, Arenas D, Moore MM, et al. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines. Vaccine. 2016. PMID: 27989627. doi:10.1016/j.vaccine.2016.11.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。